Immunic (IMUX) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChartTranscripts

IMUX Stock Forecast


Immunic stock forecast is as follows: an average price target of $5.00 (represents a 350.45% upside from IMUX’s last price of $1.11) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

IMUX Price Target


The average price target for Immunic (IMUX) is $5.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 350.45% upside from IMUX's last price of $1.11.

IMUX Analyst Ratings


Buy

According to 6 Wall Street analysts, Immunic's rating consensus is 'Buy'. The analyst rating breakdown for IMUX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Immunic Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2022Market PerformLeerink Partners$5.00$2.08139.81%350.45%
Row per page
Go to

The latest Immunic stock forecast, released on Oct 21, 2022 by Market Perform from Leerink Partners, set a price target of $5.00, which represents a 139.81% increase from the stock price at the time of the forecast ($2.08), and a 350.45% increase from IMUX last price ($1.11).

Immunic Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.11$1.11$1.11
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Immunic stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immunic's last price of $1.11. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2024EF Hutton-BuyInitialise
Sep 04, 2024Piper SandlerOverweightOverweightHold
Aug 27, 2024B. Riley-BuyInitialise
Jul 16, 2024Piper SandlerOverweightOverweightHold
Apr 05, 2024Brookline Capital-BuyInitialise
Oct 21, 2022SVB Leerink-Market PerformDowngrade
Jun 10, 2022Roth CapitalBuyBuyHold
Row per page
Go to

Immunic's last stock rating was published by EF Hutton on Sep 16, 2024. The company Initialise its IMUX rating from "null" to "Buy".

Immunic Financial Forecast


Immunic Revenue Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------------------
Avg Forecast$470.77M$452.66M$452.66M$434.56M------------$6.00K$6.00K-
High Forecast$470.77M$452.66M$452.66M$434.56M------------$6.00K$6.00K-
Low Forecast$470.77M$452.66M$452.66M$434.56M------------$6.00K$6.00K-
# Analysts1111------------42-
Surprise %-------------------

Immunic's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IMUX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Immunic EBITDA Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111------------42-
EBITDA-------------------
Avg Forecast-------------------
High Forecast-------------------
Low Forecast-------------------
Surprise %-------------------

undefined analysts predict IMUX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Immunic's previous annual EBITDA (undefined) of $NaN.

Immunic Net Income Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111------------42-
Net Income-------------------
Avg Forecast$150.23M$146.39M$148.37M$143.36M$-9.48M$-8.55M$-7.95M$-8.38M$-16.55M$-15.62M$-15.33M$-15.54M$-18.22M$-17.76M$-17.43M$-21.71M$-23.63M$-22.12M$-23.55M
High Forecast$150.23M$146.39M$148.37M$143.36M$-9.48M$-8.55M$-7.95M$-8.38M$-16.55M$-15.62M$-15.33M$-15.54M$-18.22M$-17.76M$-17.43M$-20.76M$-21.66M$-22.12M$-23.55M
Low Forecast$150.23M$146.39M$148.37M$143.36M$-9.48M$-8.55M$-7.95M$-8.38M$-16.55M$-15.62M$-15.33M$-15.54M$-18.22M$-17.76M$-17.43M$-24.54M$-24.61M$-22.12M$-23.55M
Surprise %-------------------

Immunic's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IMUX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Immunic SG&A Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111------------42-
SG&A-------------------
Avg Forecast-------------------
High Forecast-------------------
Low Forecast-------------------
Surprise %-------------------

Immunic's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IMUX last annual SG&A of $NaN (undefined).

Immunic EPS Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111------------42-
EPS-------------------
Avg Forecast$1.48$1.45$1.47$1.42$-0.09$-0.08$-0.08$-0.08$-0.16$-0.15$-0.15$-0.15$-0.18$-0.18$-0.17$-0.21$-0.23$-0.22$-0.23
High Forecast$1.48$1.45$1.47$1.42$-0.09$-0.08$-0.08$-0.08$-0.16$-0.15$-0.15$-0.15$-0.18$-0.18$-0.17$-0.21$-0.21$-0.22$-0.23
Low Forecast$1.48$1.45$1.47$1.42$-0.09$-0.08$-0.08$-0.08$-0.16$-0.15$-0.15$-0.15$-0.18$-0.18$-0.17$-0.24$-0.24$-0.22$-0.23
Surprise %-------------------

According to undefined Wall Street analysts, Immunic's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IMUX previous annual EPS of $NaN (undefined).

Immunic Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
STTKShattuck Labs$1.01$12.001088.12%Hold
IMUXImmunic$1.11$5.00350.45%Buy
CCCCC4 Therapeutics$4.01$13.50236.66%Buy
ERASErasca$2.60$6.50150.00%Buy
KZRKezar Life Sciences$7.62$17.50129.66%Buy
FHTXFoghorn Therapeutics$7.72$16.33111.53%Buy
KRONKronos Bio$0.87$1.6387.36%Buy
NRIXNurix Therapeutics$22.37$32.2043.94%Buy
EWTXEdgewise Therapeutics$31.98$45.0040.71%Buy
KYMRKymera Therapeutics$43.51$51.5018.36%Buy

IMUX Forecast FAQ


Is Immunic a good buy?

Yes, according to 6 Wall Street analysts, Immunic (IMUX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of IMUX's total ratings.

What is IMUX's price target?

Immunic (IMUX) average price target is $5 with a range of $5 to $5, implying a 350.45% from its last price of $1.11. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Immunic stock go up soon?

According to Wall Street analysts' prediction for IMUX stock, the company can go up by 350.45% (from the last price of $1.11 to the average price target of $5), up by 350.45% based on the highest stock price target, and up by 350.45% based on the lowest stock price target.

Can Immunic stock reach $2?

IMUX's average twelve months analyst stock price target of $5 supports the claim that Immunic can reach $2 in the near future.

What are Immunic's analysts' financial forecasts?

Immunic's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-34.352M (high $-34.352M, low $-34.352M), average SG&A $0 (high $0, low $0), and average EPS is $-0.339 (high $-0.339, low $-0.339). IMUX's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $1.81B (high $1.81B, low $1.81B), average EBITDA is $0 (high $0, low $0), average net income is $588.35M (high $588.35M, low $588.35M), average SG&A $0 (high $0, low $0), and average EPS is $5.81 (high $5.81, low $5.81).